News
-
New Nectr Nootropic Energy Pouches, Powered by Cognizin®, Offer a Novel Way to Stay Alert and Focused
View news »Nectr Energy recently launched their Nectr Nootropics mouth pouches featuring Cognizin® Citicoline. Focused on the energy pouch sector, the brand decided to introduce this innovative delivery system coupled with a key ingredient that was backed by research.
-
Well Traveled Releases a Novel Travel Supplement Featuring IMMUSE™
View news »Kyowa Hakko’s IMMUSE™, a research-backed postbiotic, provides immune support for travelers in this new innovative formula, “Well Traveled Immune Activator.
-
New Doctor-Formulated Energy Supplement Electrolyte Boost, Powered by Cognizin®, Boost Without Water Debuts
View news »Kyowa Hakko’s Cognizin®, a research-backed nootropic, provides brain health support in this new First-of-its-Kind formula, delivered in a simple single-serve sachet
-
Kyowa Hakko USA Celebrates Launch of CENTR Enhanced Functional Sparkling Water featuring Cognizin® Citicoline
View news »Kyowa Hakko USA is excited to announce the launch of CENTR Enhanced sparkling water, a functional beverage with a blend of nootropic and adaptogenic ingredients that includes its Cognizin® citicoline.
-
Kyowa Hakko Announces Glaxon’s Limited-Time Offer Becomes A Permanent Feature
View news »After a resoundingly successful limited-time offering, Glaxon™ has now added Kyowa Hakko’s IMMUSE™ to all SuperGreens Immune formulas. Glaxon™, producer of sports nutrition dietary supplements, launched this summer a SuperGreens Enhanced Immune Edition that, in addition to the power of Glaxon™'s trademarked Supershrooms® Organic Mushroom Blend, included IMMUSE™, a postbiotic that provides immune support at a cellular level - both of which support the immune systems of its customers.
-
Cognizin® Citicoline Launches “Tap Challenge” In the App Store
View news »The Tap Challenge App is finally here for professional button mashers or anyone who wants to challenge themselves each day!
-
Manufacturing strain of Kyowa Hakko Bio’s 2'-fucosyllactose, a human milk oligosaccharide (HMO), passed safety evaluation in China
View news »KYOWA HAKKO BIO CO., LTD. (Kyowa Hakko Bio) is pleased to announce that its manufacturing strain used for producing 2'-fucosyllactose (2’-FL), the most abundant HMO in human milk, has passed the safety evaluation by the Chinese Ministry of Agriculture and Rural Affairs (MARA), while other manufacturing strains used for producing 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL) are currently under review.
-
Dr. Eri Nakazaki of the Kirin Central Research Institute Wins JSBBA Award for Her Work Developing a Health Food Ingredient to Support Memory
View news »One of Kyowa Hakko’s own is honored for the enhancement of citicoline, which helps healthy elderly adults improve memory function
-
Kyowa Hakko USA Announces the Appointment of Dr. Colin Hill to the Scientific Advisory Board of Award-Winning Postbiotic IMMUSE™
View news »With an impressive background in mining the microbiome for novel therapies, Prof. Hill helped with the definition of a postbiotic as a part of ISAPP.
-
Kyowa Hakko USA Announces the Appointment of Dr. Heather Moday as an Educational Partner for IMMUSE™ LC-Plasma
View news »With a special interest in immune system dysfunction, including autoimmunity, allergy, and the stress-immune connection, Dr. Moday puts IMMUSE™, an award-winning postbiotic, at the forefront of ingredients to look out for in nutritional supplements.